Mirum Pharmaceuticals Inc MIRM
News
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli